Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018.

Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018.
复制标题

在产生KPC的Klebsiella肺炎中,MeropeNem/Vaborbactam耐药性的流行病学,导致意大利北部的血液感染,2018年。

DOI:
10.3390/antibiotics10050536
复制
发表时间:
2021-05-06
期刊:
Antibiotics (Basel, Switzerland)
影响因子:
--
通讯作者:
Ambretti S
Ambretti S
中科院分区:
其他
文献类型:
--
作者:
Gaibani P;Lombardo D;Bussini L;Bovo F;Munari B;Giannella M;Bartoletti M;Viale P;Lazzarotto T;Ambretti S

文献摘要

参考文献

被引文献

相似文献

美罗培南/瓦博巴坦(MEM-VAB)是一种新型的碳青霉烯-β-内酰胺酶抑制剂,对产KpC的肠杆菌有明显的抑制作用。在此,我们评估了意大利一家大型医院产KPC肺炎克雷伯菌(KPC-KP)血流感染中美罗培南/万宝巴坦耐药的发生率。8%(n=5)的KPC-KP对美罗培南/阿波巴坦耐药,5%(n=3)的KPC-KP对头孢他啶/阿维巴坦(CAZ-AVI)交叉耐药。基因组分析表明,美罗培南/瓦博巴坦耐药与OmpK35截短和在OmpK36第134-135位插入甘氨酸和天冬氨酸有关(GD134-135)。值得注意的是,没有特定的突变与交叉耐药有关。没有特定的抗菌药治疗与良好的临床结果相关,而交叉耐药与更高的临床和/或微生物失败无关。我们的研究表明,对美罗培南/瓦博巴坦的耐药性是由孔蛋白突变引起的,并与头孢他啶/阿维巴坦和碳青霉烯类抗生素的敏感性降低有关。
Meropenem/Vaborbactam (MEM-VAB) is a novel carbapenem- β-lactamase inhibitor active against KPC-producing Enterobacteria. Herein, we evaluate the incidence of meropenem/vaborbactam-resistance among KPC-producing K. pneumoniae (KPC-Kp) bloodstream infection in a large Italian hospital. Meropenem/vaborbactam-resistance was found in 8% (n = 5) KPC-Kp, while 5% (n = 3) strains exhibited cross-resistance to ceftazidime/avibactam (CAZ-AVI). Genomic analysis revealed that meropenem/vaborbactam-resistance was associated with truncated OmpK35 and insertion of glycine and aspartic acid within OmpK36 at position 134–135 (GD134–135). Notably, no specific mutation was associated to cross-resistance. No specific antimicrobial treatment was related to favorable clinical outcomes, while cross-resistance was not associated to higher clinical and/or microbiological failures. Our study indicated that resistance to meropenem/vaborbactam was due to porins mutations and is associated with reduced susceptibility to both ceftazidime/avibactam and carbapenems.
DOI: 10.2807/1560-7917.es2014.19.42.20939
发表时间: 2014-10-23
期刊: EUROSURVEILLANCE
影响因子: 19
作者:
Monaco, M.;Giani, T.;Rossolini, G. M.
通讯作者: Rossolini, G. M.
DOI: 10.1136/gutjnl-2017-314324
发表时间: 2018-10-01
期刊: GUT
影响因子: 24.5
作者:
Piano, Salvatore;Bartoletti, Michele;Angeli, Paolo
通讯作者: Angeli, Paolo
DOI: 10.1099/jmm.0.012575-0
发表时间: 2009-10-01
影响因子: 3
作者:
Landman, David;Bratu, Simona;Quale, John
通讯作者: Quale, John
DOI: 10.1016/j.tim.2014.09.003
发表时间: 2014-12
影响因子: 15.9
作者:
Chen, Liang;Mathema, Barun;Chavda, Kalyan D.;DeLeo, Frank R.;Bonomo, Robert A.;Kreiswirth, Barry N.
通讯作者: Kreiswirth, Barry N.
DOI: 10.1007/s40121-018-0214-1
发表时间: 2018-12
影响因子: 5.4
作者:
Wunderink RG;Giamarellos-Bourboulis EJ;Rahav G;Mathers AJ;Bassetti M;Vazquez J;Cornely OA;Solomkin J;Bhowmick T;Bishara J;Daikos GL;Felton T;Furst MJL;Kwak EJ;Menichetti F;Oren I;Alexander EL;Griffith D;Lomovskaya O;Loutit J;Zhang S;Dudley MN;Kaye KS
通讯作者: Kaye KS